Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

What data says about Tukaram Mundhe’s 100-day stint as FDA Commissioner

When compared with the data in the year 2025-26, the last three months have seen a 557% increase in the number of complaints received, 378% increase in investigation of complaints, and a 217% increase in the number of searches and seizures.

What data says about Tukaram Mundhe’s 100-day stint as FDA Commissioner

Over the past three months, the Food and Drug Administration (FDA) has ramped up regulatory actions against drug manufacturers and sellers, according to data analyzed by The Hindu. Inspections of Ayurvedic manufacturers have surged from 203 in 2021-22 to 427 in the last quarter of 2026. Complaints received, investigations, and searches/seizures have also seen significant increases – 557%, 378%, and 217% respectively.

The average number of monthly regulatory actions has risen from around 258 to 293 since June-August 2026. FDA Commissioner Tukaram Mundhe, who recently completed 100 days in office, highlighted the use of an automated system to track complaints and the corresponding increase in enforcement metrics. Common violations include discrepancies in Batch Manufacturing Records, testing by inadequate personnel, absence of Annual Product Quality Reviews, and improper storage of temperature-sensitive drugs.

FDA emphasized its commitment to ensuring safe, quality medicines and rigorous action against non-compliant establishments.

Written by urgent.news from The Hindu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at thehindu.com →

More in Health & Medicine

More from Tuesday 8 September →